Rationale for the use of sphingosine analogues in COVID-19 patients
Deborah R Tasat and Juan S Yakisich
DOI: https://doi.org/10.7861/clinmed.2020-0309
Clin Med January 2021 Deborah R Tasat
ANational University of San Martin, San Martin, and University of Buenos Aires
Roles: associate professor
Juan S Yakisich
BHampton University, Hampton, USA
Roles: assistant professor
Article Information
vol. 21 no. 1 e84-e87
PubMed:
Published By:
Print ISSN:
Online ISSN:
History:
- Published online January 21, 2021.
Article Versions
- Latest version (November 3, 2020 - 00:30).
- You are viewing the most recent version of this article.
Copyright & Usage:
© Royal College of Physicians 2021. All rights reserved.
Author Information
- ANational University of San Martin, San Martin, and University of Buenos Aires
- BHampton University, Hampton, USA
- Address for correspondence: Dr Juan S Yakisich, 200 William R Harvey Way, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA 23668, USA. Email: juan.yakisich{at}hamptonu.edu
Article usage
Article Tools
Rationale for the use of sphingosine analogues in COVID-19 patients
Deborah R Tasat, Juan S Yakisich
Clinical Medicine Jan 2021, 21 (1) e84-e87; DOI: 10.7861/clinmed.2020-0309
Citation Manager Formats
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.